Acrivon Therapeutics, Inc. (ACRV)
NASDAQ · Manufacturing · Pharmaceutical preparations
ACRV price, last 12 months
Key stats
- Previous close
- $2.12
- Open
- $2.12
- Day range
- $2.07 – $2.13
- 52-week range
- $1.27 – $3.56
- Volume
- 182K
- Avg volume (20 days)
- 319.3K
- Market cap
- $90.0M
Performance
Technicals and fundamentals
About Acrivon Therapeutics, Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $90.0M